Jim Simons Humanigen, Inc Transaction History

Renaissance Technologies LLC

  • $56.7 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
SELL
$0.13 - $0.2 $10,335 - $15,900
-79,500 Reduced 81.37%
18,200 $3,000
Q1 2023

May 12, 2023
SELL
$0.12 - $0.23 $167,288 - $320,636
-1,394,071 Reduced 93.45%
97,700 $14,000
Q4 2022

Feb 13, 2023
BUY
$0.09 - $0.2 $56,346 - $125,214
626,071 Added 72.32%
1,491,771 $179,000
Q3 2022

Nov 14, 2022
BUY
$0.15 - $3.02 $129,855 - $2.61 Million
865,700 New
865,700 $156,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email